title: Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infections.
abstract: Wilson et al. (Am. J. Surg. 185:369-375, 2003) developed a disease severity classification system for use in complicated skin and skin structure infections (cSSSI). Two phase 3 trials of ceftaroline fosamil in cSSSI provided the opportunity to evaluate the association between Wilson Severity Risk Class and clinical cure rates. Our analyses did not confirm that an association exists between Wilson Severity Risk Class and clinical cure rate and, thus, did not validate its predictive utility.
authors.affiliation: Cerexa, Inc., Oakland, California, USA. ghtalbot@gmail.com
authors.forename: George H
authors.initials: GH
authors.lastname: Talbot
authors.forename: Tanya
authors.initials: T
authors.lastname: O'Neal
authors.forename: Anita F
authors.initials: AF
authors.lastname: Das
authors.forename: Dirk
authors.initials: D
authors.lastname: Thye
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013291:Streptococcus / Q000187:drug effects* / Q000254:growth & development
chemical_list: D000900:Anti-Bacterial Agents